# Casgevy sales reach $76M in Q2 2026, up 151% on a year earlier; approved in 39 countries

Canonical page: https://technooptimist.io/stories/casgevy-sales-reach-76m-in-q2-2026-up-151-on-a-year-earlier-approved-in-2282c4f2
Date: 3 Aug 2026
About: [CRISPR Therapeutics](https://technooptimist.io/companies/crispr-therapeutics.md) · [Casgevy (exa-cel)](https://technooptimist.io/biotech/casgevy.md)
Original source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm

Vertex booked $76M of Casgevy revenue in the second quarter of 2026, up 78% on the previous quarter and 151% on a year earlier, helped by more infusions outside the US. The therapy is now approved in 39 countries, and Vertex is working on gentler bone-marrow preparation that could widen who can get it.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.